Overview

Cognitive and Neurophysiological Effects of Raloxifene in Alzheimer's Disease

Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to determine the effectiveness of treatment with raloxifene, an estrogen-like medication approved by the Food and Drug Administration for the treatment of osteoporosis, in improving memory and the ability to live independently in postmenopausal women with Alzheimer's disease.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborator:
National Institute on Aging (NIA)
Treatments:
Raloxifene Hydrochloride